Rationale

A standard of care treatment for muscle-invasive bladder cancer (MIBC) is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection (RC-PLND), leaving most patients with an external drainage bag to collect their urine (urostomy). This surgery is associated with a risk for significant postoperative complications and substantially impacts quality of life.

Retrospective studies have found that select patients who have clinical down-staging of their MIBC following chemotherapy, as assessed by post-chemotherapy cystoscopy, can be managed with close surveillance without a cystectomy. These patients can achieve long-term bladder-intact disease-free survival rates, but there is a risk for both muscle-invasive and metastatic recurrences.

Alterations within certain DNA damage response (DDR) genes are associated with significant sensitivity to cisplatin-based chemotherapy in bladder cancer and are emerging as a predictive biomarker of chemotherapy response.

This study will attempt to identify a subset of patients with DDR mutant MIBC who can be managed with cisplatin-based chemotherapy alone and avoid RC-PLND (an organ-sparing approach). If this study meets its primary endpoint, it would lead to a paradigm shift in the management of MIBC patients with DDR gene alterations.
Objective

Primary
- To determine the 3-year event free survival, defined as the proportion of patients without invasive or metastatic recurrence following definitive dose dense gemcitabine and cisplatin chemotherapy in those patients whose pre-treatment TURBT tumors harbor deleterious DDR gene alterations and who achieve <cT1 response to chemotherapy.

Secondary
- To determine the clinical response rate (<cT1) for patients harboring deleterious DDR gene alterations following dose dense gemcitabine and cisplatin.
- To determine the bladder-intact and overall survival for DDR-altered patients with <cT1.
- For DDR gene altered patients who elect radical cystectomy despite <cT1, to determine the pT0 rate in this patient population.
Alliance A031701: A Phase II Study of Dose-dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Gopa Iyer, MD
Memorial Sloan Kettering Cancer Center

Study Schema

Rationale
Objective
Study Schema
Treatment Plan
Key Eligibility Criteria
Follow Up

Please use the headings above to navigate through the different sections of the poster.
Treatment Plan

Rationale
- Protocol treatment is to begin ≤ 7 days from registration.
- There are three registration steps in this trial:
  - **Step 1 Registration**: Eligible patients are registered and will begin chemotherapy within 7 days of registration. Patients will receive a total of 6 cycles of chemotherapy. Those patients receiving at least 4 cycles of chemotherapy will proceed to Step 2 Registration. Patients receiving <4 cycles of chemotherapy will proceed to radical cystectomy.
  - **Step 2 Registration**: At Step 2 registration, sites will use the DDR test results they have received to determine future therapy. Patients without a DDR gene alteration will undergo a radical cystectomy or proceed to chemo-radiotherapy. Patients with a DDR gene alteration will undergo a cystoscopy and then proceed to Step 3 registration.
  - **Step 3 Registration**: Patients with a DDR gene alteration will proceed to Step 3 registration. Based on the results of the cystoscopy, patients will proceed to either bladder sparing or definitive local therapy with either a radical cystectomy or chemo-radiotherapy.

Study Schema
- **Chemotherapy**
  - Chemotherapy will be given on an outpatient basis, with a total of 6 cycles administered every 14 days. Administration ≤ +/- 1 day of schedule will not be considered a protocol violation. Treatment will continue until disease progression or unacceptable adverse event for a maximum period of 12 weeks. Patients need to complete at least 4 cycles of chemotherapy to proceed to Step 2 registration.

- **Surgery**
  - Patients receiving at least 4 cycles of chemotherapy will be registered again (Step 2). (Patients receiving <4 cycles of chemotherapy will proceed to a radical cystectomy.) Patients will fit into 1 of 2 categories, based on their DDR gene sequencing results:
    - **Radical cystectomy or chemo-radiotherapy**: Those patients whose tumors do not harbor deleterious DDR gene alterations, or patients whose pre-treatment TURBT specimens do harbor a deleterious DDR gene alteration but have any degree of residual invasive disease or post-chemotherapy cystoscopic evaluation or radiographic suspicion for invasive disease (≥cT1) will undergo definitive local therapy, either radical cystectomy or chemoradiotherapy, as per the local investigator’s discretion.
    - **Bladder Sparing**: If pre-treatment TURBT tissue contains a deleterious DDR gene alteration, patients will be offered the possibility of foregoing definitive local therapy if they achieve a clinical complete response or non-invasive residual disease (CIS/cTa) on a post-chemotherapy cystoscopic evaluation. This evaluation MUST include an aggressive TURBT of the prior site of MIBC.

- **Chemoradiotherapy** (alternative to radical cystectomy) for patients electing for an organ-sparing approach despite not meeting genomic and/or clinical criteria for Arm D

Key Eligibility Criteria

Follow Up

Please use the headings above to navigate through the different sections of the poster.
Key Eligibility Criteria

- Histologically confirmed urothelial carcinoma of the bladder
- Twenty unstained slides or 1 FFPE block from pretreatment TUR available
- Clinical stage T2-T4aN0/xM0
- Candidate for radical cystectomy
- No prior systemic chemotherapy or radiation therapy for the bladder (prior BCG therapy is allowed)
- No major surgery or RT 4 weeks prior to enrollment
- Non-pregnant and non-nursing
- Age > 18 years
- ECOG PS = 0-1
- Cr Clearance >55 mL/min
Alliance A031701: A Phase II Study of Dose-dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Gopa Iyer, MD
Memorial Sloan Kettering Cancer Center

Rationale

Alliance A031701 is funded by the National Institutes of Health through National Cancer Institute grant awards.

Contact Us

Study Chair: Gopa Iyer, MD
Memorial Sloan Kettering Cancer Center
E-mail: iyerg@mskcc.org
Phone: 646-888-4737

Protocol Coordinator: Colleen Watt
E-mail: cboyle@uchicago.edu
Phone: 773-702-4670